Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efinopegdutide PK/PD study in healthy Chinese participants
NCT06836037Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2022
- Primary completion
- Feb 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of efinopegdutide in Nonalcoholic steatohepatitis (NASH) and obesity (5 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience an Adverse Event (AE) at 112 days, Number of Participants Who Discontinue Study Treatment Due to an AE at 78 days and 15 more. Started Sep 2022; status: completed.
02
Drugs
efinopegdutide
03
Conditions
Nonalcoholic steatohepatitis (NASH)obesity
Beyond the preview
Go deeper on NCT06836037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06836037.